

# Lydia L. Benitez, PharmD, BCOP

(Lydia L. Benítez Colón)

1540 East Medical Drive, CW7 Room 251B

Ann Arbor, MI 48109

787-630-6458 [lbenitez@umich.edu](mailto:lbenitez@umich.edu)

## Education and ASHP Accredited Post-Graduate Training

---

<b>Post Graduate Year Two Hematology/Oncology Pharmacy Residency</b>	Jul 2015-Jun 2016
<i>University of Michigan Health System, Ann Arbor, MI</i>	
<i>Residency Director: Shawna Kraft, PharmD, BCOP</i>	
<b>Post Graduate Year One Pharmacy Practice Residency</b>	Jul 2014-Jun 2015
PGY1 Chief-Resident	
<i>University of Michigan Health System, Ann Arbor, MI</i>	
<i>Residency Director: John Clark, PharmD, MS, BCPS</i>	
<b>Doctor of Pharmacy</b>	Sep 2010-Apr 2014
Graduated with High Distinction	
<i>University of Michigan College of Pharmacy, Ann Arbor, MI</i>	
<b>Bachelor of Science – Biology</b>	Sep 2005-Dec 2009
<i>University of Michigan College of Literature, Science &amp; the Arts, Ann Arbor, MI</i>	

## Certifications and Licenses

---

<b>Board of Pharmacy Specialties - Board Certified Oncology Pharmacist #5150688</b>	Jul 2017-Present
<b>Michigan Board of Pharmacy, Pharmacist License #5302040302 (exp 7/2025)</b>	Jul 2014-Present
<b>Michigan Board of Pharmacy, Controlled Substance License #5302040302 (exp 7/2025)</b>	Jul 2014-Present
<b>University of Michigan Health System &amp; College of Pharmacy Teaching Certificate</b>	Awarded Jul 2015
<b>APhA Pharmacy Based Immunization Delivery Certification</b>	Awarded Jun 2011

## Honors and Awards

---

<b>MICHR Clinical and Translational Research Faculty Peer Mentor Award</b>	Jul 2025
<i>Michigan Institute for Clinical &amp; Health Research recognition of faculty who demonstrate consistent, high-quality mentoring in areas of clinical and translational research.</i>	
<b>HOPA Basic Science &amp; Clinical Research Literature Award</b>	Mar 2022
<i>Recognizes a scientific article describing hematology/oncology basic science and/or translational research or clinical trials evaluating drug efficacy and/or safety.</i>	
<b>Michigan Medicine Pharmacy Residency Program Preceptor of the Year</b>	Jun 2021
<i>Honor bestowed upon one exceptional Michigan Medicine preceptor, who is not only excellent role model for learners but have demonstrated commitment to the core values of the Residency Programs.</i>	
<b>Michigan Medicine Oncology Pharmacy Preceptor of the Year</b>	Jun 2020
<i>Awarded to one oncology preceptor who has shown outstanding support for our residents and the oncology residency program.</i>	
<b>University of Kentucky APPE Preceptor of the Year Nominee</b>	Sep 2019
<i>Nominated by APPE students precepted on Oncology Inpatient rotation APPE.</i>	
<b>UKHealthcare Pharmacy Department Rookie of the Year Award</b>	Jun 2018
<b>UKHealthcare Pharmacy Department Rookie of the Year Award</b>	Sep 2017

*Awarded to one pharmacist who demonstrates exceptional work ethic and teamwork within the first year of employment.*

<b>Julia E. Emanuel Award</b> <i>Awarded to a graduating PharmD student for community service, leadership, and academic performance</i>	May 2014
<b>The Honor Society of Phi Kappa Phi, University of Michigan</b>	Dec 2013
<b>Rho Chi Academic Honor Society, University of Michigan Alpha Chapter</b>	Apr 2013

## **Clinical Service Appointments**

---

<b>Director of Pharmacist of POEM and Oncology Stewardship</b> <i>Pharmacist Optimizing Oncology Care Excellence in Michigan initiative Michigan Oncology Quality Consortium, Ann Arbor, MI Program Director: Jennifer Griggs, MD, MPH, FACP, FASCO</i>	Sep 2025-Present
<b>Adult Outpatient Leukemia Pharmacist Specialist</b> <i>Michigan Medicine, University of Michigan, Ann Arbor, MI Director: Vishnuprabha Vogel, PharmD, BCOP</i>	Aug 2018-Sep 2025
<b>Hematology/Oncology Clinical Specialist – Inpatient/Outpatient Malignant Hematology and Hematopoietic Cell Transplant</b> <i>University of Kentucky Healthcare, Lexington, KY Supervisor: Amber Lawson, PharmD, BCOP</i>	Aug 2016-Jul 2018
<b>Cancer Center Infusion Pharmacy Staff Pharmacist</b> <i>University of Michigan Cancer Center, Ann Arbor, MI Supervisor: Kelly Procailo, PharmD</i>	Jul 2015-Jun 2016
<b>Inpatient Clinical and Staff Pharmacist – Pharmacokinetic, Anticoagulation, Nutrition, and Staffing</b> <i>Michigan Medicine, Ann Arbor, MI Supervisor: Pamela Walker, PharmD, BCPS &amp; Kathy Kinsey, RPh</i>	Jul 2014-Jun 2016

## **Academic Appointments**

---

<b>Clinical Associate Professor</b> <i>University of Michigan College of Pharmacy, Ann Arbor, MI Supervisor: Manjunath (Amit) Pai, PharmD, FCP</i>	Sep 2024-Present
<b>Clinical Assistant Professor</b> <i>University of Michigan College of Pharmacy, Ann Arbor, MI Supervisor: Manjunath (Amit) Pai, PharmD, FCP</i>	Jul 2020-Aug 2024
<b>Adjunct Clinical Pharmacy Instructor</b> <i>University of Michigan College of Pharmacy, Ann Arbor, MI</i>	Aug 2018-Jun 2020
<b>Adjunct Professor, Pharmacy Practice and Science</b> <i>University of Kentucky, Lexington, KY</i>	Feb 2017-Jul 2018

## **Peer-Reviewed Publications**

^corresponding author, \*denotes trainee (PharmD student or resident, or medical fellow)

- 
1. Shinn LT\*, King MA, Brown J, Fraga M; **Benitez LL**, et al. It's "blin" a long time coming: the rise of blinatumomab in Philadelphia chromosome-negative acute lymphoblastic leukemia. *Clin Lymphoma Myeloma Leuk*. 2025 Aug 15:S2152-2650(25)00283-6.
  2. Gabbard T\*, Perissinotti AJ, Benitez LL, Fraga M, Pettit KM, et al. Impact of Chemotherapy Educational Videos for Patients with Acute Myeloid Leukemia. *J Cancer Educ*. 2025 Feb;40(1):73-78. doi: 10.1007/s13187-024-02473-2. Epub 2024 Jul 2.
  3. **Benitez L**<sup>^</sup>, Marx KR, Rausch C, Buhlinger KM, Clark SM, et al. Multicenter Retrospective Evaluation of Treatment of High Risk Acute Promyelocytic Leukemia (APL): Results from the Hematology Research Outcomes (HERO) Consortium. *Am J Hematol*. 2025 Jun;100(6):1094-1097. doi: 10.1002/ajh.27667.
  4. Gabbard T\*, Marini BL, Mirza KM, **Benitez L**, Fraga M, et al. Therapeutic outcomes of patients with acute erythroid leukemia treated with hypomethylating agents. *J Oncol Pharm Pract*. 2025 Mar 2:10781552251323578. doi: 10.1177/10781552251323578.
  5. Griffin SP, Signorelli J, Raheem F, Adler K, **Benitez LL**, et al. Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network. *J Oncol Pharm Pract*. 2025 Apr 1:10781552251330252. doi: 10.1177/10781552251330252.
  6. Ahmed I, Nachar V, **Benitez L**, Carty SA, Sano D, et al. Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma. *Blood*. 2024:144 (Supplement 1): 3105. <https://doi.org/10.1182/blood-2024-205406>
  7. Shinn LT\*, **Benitez LL**, Perissinotti AJ, Reid JH, Buhlinger KM, et al. Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia. *International Journal of Hematology*. 2024. 118(6):682-689.
  8. Foucar CE, Foley DH, Aldous J, Burke PW, Pettit KR, **Benitez LL**, et al. Real-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan. *Eur J Haematol*. 2024 Mar;112(3):424-432.
  9. Khouderchah CJ\*; **Benitez LL**; Marini BL; Fraga M; Pettit K; Burke PW; Bixby DL; Perissinotti AJ. Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up. *Leukemia and Lymphoma*. 2024. 65(2):228-234.
  10. Coe-Eisenberg, TD\*, Perissinotti, AJ, Marini BL, Pettit, K, Bixby, DL, Burke P, **Benitez, L**<sup>^</sup>. Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring. *Annals of Hematology*. 2023 Nov;102(11):3133-3141.
  11. Varabyeva A\*, Pui-See Lo, C, Brancaccio A, Perissinotti AJ, Patel T, Sandison K, **Benitez LL**, et al. Impact of number of lumens in central-venous catheters on central-line bloodstream infection (CLABSI) and venous thromboembolism (VTE) risk in patients with acute leukemia. *Infect Control Hosp Epidemiol*. 2023 Jan;44(1):125-127.
  12. Bazzell BG\*, Marini BL, **Benitez LL**, Bixby D, Burke P, Pettit K, Perissinotti AJ. Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study. *J Oncol Pharm Pract*. 2021 Jun 1:10781552211020815.
  13. Ochs MA\*, Marini BL, Perissinotti AJ, Foucar CE, Pettit K, Burke P, Bixby DL, **Benitez LL**<sup>^</sup>. Oncology stewardship in acute myeloid leukemia. *Ann Hematol*. 2022 Aug;101(8):1627-1644
  14. Chen Y\*, Buhlinger K, Perissinotti AJ, Schepers AJ, **Benitez L**, Auten J, Chen SL, Bixby DL, Burke PW, Pettit KM, Marini BL. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients

- 
- receiving PEG-asparaginase. *Leuk Lymphoma*. 2022 Jun 14:1-8.
15. Ochs MA\*, Marini BL, **Benitez LL**, Stump SE, Weis TM, Buhlinger KM, Diaz T, Reid JH, Muluneh B, Pettit K, Burke P, Bixby DL, Perissinotti AJ. Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia. *Leuk Lymphoma*. 2022 Mar 28:1-10.
  16. Yoon, JJ\*, **Benitez, LL**, Bixby, DL, Burke, PW, Marini, BL, Perissinotti, AJ, ... & Pettit, KM. Efficacy of HMA+/- Venetoclax or intensive chemotherapy in blast-phase myeloproliferative neoplasms. *Blood*, 138. 2021; 2569.
  17. Homan MJ\*, Reid JH, Nachar VR, **Benitez LL**, Brown AM, et al. Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management. *Support Care Cancer*. 2021; 29(11):6505-6510.
  18. Bazzell BG\*, **Benitez LL**, Marini BL, Perissinotti AJ, Phillips TJ, Nachar VR. Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2021 May;21(5):295-308.
  19. Perissinotti AJ, **Benitez LL**, Marini BL. Oral Azacitidine Maintenance for Acute Myeloid Leukemia. *N Engl J Med*. 2021 Apr 1;384(13):e51.
  20. **Benitez LL**^, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, et al. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. *Leuk Lymphoma*. 2021: 021, AHEAD-OF-PRINT, 1-9.
  21. Geer MJ, Foucar CE, Devata S, **Benitez L**, Perissinotti AJ, et al. Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed. *J Natl Compr Canc Netw* 2021 Aug 17;19(11):1272-1275
  22. King D, Foucar CE, Ma V, **Benitez L**, Perissinotti AJ, et al. Identification of variant APL translocations PRKAR1A-RAR $\alpha$  and ZBTB16-RAR $\alpha$  (PLZF-RAR $\alpha$ ) through the MI-ONCOSEQ platform.
  23. Ravi K, Franson A, Homan MJ, Roberts H, Pai MP, Miklja Z, He M, Wen B, **Benitez LL**, et al. Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. *Leuk Lymphoma*. 2021;7:1-6. *Cancer Genet*. 2021 Nov;258-259:57-60.
  24. Reid J\*, Perissinotti AJ, **Benitez L**, et al. Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts. *Leuk Res*. 2021 Feb 19;103:106539.
  25. Reid J\*, Marini B, **Benitez L**, Pettit K, Bixby D, et al. Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2021 Jun;21(6):393-400.e1.
  26. Ochs M\*, Perissinotti A, Marini B, Burke P, ..., **Benitez L**^ . Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia. *Leuk Res*. 2021 Jan;102:106517.
  27. Stonerock D\*\*Homan M, Marini B, Perissinotti AJ, Bixby D, Burke P, Pettit K, **Benitez L**^ . AML-287: A Single-Center Comparison of Decitabine  $\pm$  Venetoclax or FLAG in the Treatment of Secondary Acute Myeloid Leukemia. *Clinical Lymphoma Myeloma & Leukemia*. 2020.20:s210.
  28. Reid JH\*, Perissinotti AJ, **Benitez L**, Bixby DL, Burke P, et al. Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. *Leuk Lymphoma*. 2020. 61(4):862-868.
  29. Hickey E\*, Clemons B, Griffin S, Cox J, Sutphin S, Ramlal R, **Benitez L**^ . Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia. *Leuk*

---

*Lymphoma*. 2019 Dec;60(14):3557-3560.

30. Marini BL, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, **Benitez LL**<sup>A</sup>. Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? *Cancer*. 2019 Nov 1;125(21):3890-3891.
31. **Benitez, LL.**; Carver, Peggy L. Adverse Effects Associated with Long-Term administration of Azole antifungal Agents. *Drugs*. 2019;79(8), 833-853.
32. Alsawah F, **Benitez L**, Choi S, Marini B, Perissinotti A, et al. Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. *Blood Adv*, 2019.Nov 12;3(21):3333-3336.
33. Marini B, Brown J, **Benitez L**, Walling E, Hutchinson RJ, et al. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. *Leuk Lymphoma*, 2019. May 17:1-15.
34. Cheung E\*, Perissinotti AJ, Bixby DI, Burke PW, Pettit KM, **Benitez LL**, et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. *Ann Hematol*, 2019.9893:541-559.
35. Oh, M; Marini, B, Perissinotti, A, **Benitez, L.**, Burke, PW, Bixby, DL,...&McBride, A. Bayesian network meta-analysis (NMA) of complete remission without or with incomplete hematologic recovery (CR/CRi) to CPX-351, FLAG, and standard 7+3 (7+3) chemotherapy in the treatment of newly diagnosed secondary acute myeloid leukemia (sAML). *Journal of Clinical Oncology*. 2019; 37(15).
36. Ratermann K, Cox J, **Benitez L**, Davis F. Drugs that act on the immune system: cytokines and monoclonal antibodies. In: Ray SD. Side Effects of Drugs Annual. Vol.40. Massachusetts: Elsevier. 2018. Ch.36: 477-487.
37. Rausch CR, Marini BL, **Benitez L**, Elias A, Burke PW, et al. PEGing down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. *Leuk Lymphoma*, 2018. 59(3):617-624.
38. Tang L, Marini B, **Benitez L**, Nagel J, Berglund C, et al. Risk factors for subtherapeutic levels of posaconazole tablets. *Journal of Antimicrobial Chemotherapy*, 2017. 72(10):2902-2905.
39. Marini BL, **Benitez L**, Zureick AH, Salloum R, Gauthier AC, et al. Blood-brain-barrier-adapted precision medicine therapy for pediatric brain tumors. *Translational Research*, 2017. 188:27.e1-27.e14.
40. **Benitez L**, Gharibian K, Frame D, Mody R, Mora E. Clofarabine dosing in a patient with AML on intermittent hemodialysis: Case report and review of the literature. *JPHO*, 2017. 39(6):481-484.
41. Mackler E, Petersen L, Severson JA, Blayney D, **Benitez L**, et al. Implementing a method for evaluating patient reported outcomes associated with oral oncolytic therapy. *JOP*, 2017. 13(4):e395-e400.
42. Kaminsky B, **Benitez L**, Bostwick J, Early C, Klein K. Benefits of a concentrated teaching rotation: Perspectives of pharmacy residents and faculty. *Currents in Pharmacy Teaching and Learning*, 2017. 9(2017)4-8.
43. Koschmann C, Marini B, **Benitez Colon L**, Wu Y, Kumar C, et al. PDCT-03. Clinically integrated sequencing in the management of children with high-risk brain tumors. *Neuro-Oncology*, 2016. 18, Suppl.16
44. **Benitez L**, Perissinotti A, Santarossa M, Marini B. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. *Pediatr. Blood Cancer*, 2015. 62(6):1115.

---

## Poster and Professional Presentations (selected)

---

### National Conferences

Philadelphia-like Acute Lymphoblastic Leukemia: Understanding and Closing a Health Disparity. BCOP and APCE accredited presentation. American College of Clinical Pharmacy

Oct 2025

(ACCP) Annual Meeting. Minneapolis, MN.

Biomarker testing for metastatic non-small cell lung cancer across Michigan Oncology Quality Consortium (MOQC) sites. Poster presented at 2025 American Society of Clinical Oncology (ASCO) Quality Care Symposium. Oct 2025

OCC and POPBC Collaboration: Data for current oncology pharmacy practice and justification for future positions. HOPA Practice Management webinar series. Jun 2025

Frontline management of Acute Lymphoblastic Leukemia. Association of Cancer Care Centers (ACCC) webinar. *ACCC Task Force for community-based insights*. Dec 2024

Whitesell A, Ahmed I, Brown J, King M, Fraga M, Marini B, Perissinotti A, Benitez L. Influence of patient residence on outcomes of Acute Lymphoblastic Leukemia. Poster. *Presented at 2024 Hematology Oncology Pharmacist Association Annual Meeting Pre-Conference*, Tampa, FL. Mar 2024

Multicenter Retrospective Evaluation of Treatment of High Risk Acute Promyelocytic Leukemia (APL): Results from the Hematology Research Outcomes (HERO) Consortium . Poster. *Presented at 2023 American Society of Hematology Conference*. San Diego, CA. Dec 2023

Giving orphan drugs a home: A case-based approach to the management of rare leukemic entities. BCOP and ACPE accredited presentation. *2023 Hematology Oncology Pharmacist Association Annual Meeting Annual Conference*. Phoenix AZ. Mar 2023

VEN-ting about Novel Therapies in AML. ACPE Accredited presentation. *2022 Advanced Topics in Oncology Pharmacy Practice*. San Diego, CA. Jul 2022

Optimizing Precepting Strategies and Residency Program Management. ACPE accredited presentation. *2022 Hematology Oncology Pharmacist Association Annual Meeting Pre-Conference*. Boston, MA Mar 2022

Clark KA, Marini BL, Perissinotti AJ, Benitez LL. Retrospective Evaluation of Opioid Use In the Inpatient Acute Leukemia Population. Poster. *Presented at 2021 Hematology Oncology Pharmacist Association Annual Meeting, Virtual*. Apr 2021

Stonerock D, Homan M, Marini B, Perissinotti A, Bixby D, Pettit K, Burke P, Benitez L [primary investigator]. A single-center comparison of decitabine ± venetoclax or FLAG in the treatment of secondary AML. Abstract 387. *Presented at 2020 Society of Hematologic Oncology, Virtual*. Aug 2020

Homan M, Perissinotti A, Marini B, Burke P, Bixby D, Pettit K, Benitez L [primary investigator]. Outcomes in Patients with Acute Myeloid Leukemia Receiving 10-day Decitabine with or without Venetoclax. *2020 Hematology/Oncology Pharmacy Association Annual Conference*. Tampa, FL. Mar 2020

Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, et al. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Poster. *Presented at 2019 American Society of Hematology*. Orlando, FL. Dec 2019

Evolving Therapies in Acute Myeloid Leukemia. ACPE accredited presentation. *Transplantation & Cellular Therapy Meetings, Pharmacist Conference*. Houston, TX. Feb 2019

Cheung E, McKenzie MG, Benitez Colon L, Kaye KS, Petty L, et al. Impact of Standard versus Prolonged Courses of Antibiotics for the Treatment of Uncomplicated Oct 2018

Staphylococcus aureus Bacteremia (SAB) in Patients with Hematologic Malignancies. <i>2018 ID Week. San Francisco, CA.</i>	
Corbett D, Adams V, Benitez Colon L, Cox J, Brignola M, et al. Anticoagulation in the setting of thrombocytopenia in cancer patients. <i>2018 Hematology/Oncology Pharmacy Association Annual Conference. Denver, Co.</i>	Mar 2018
Hickey E, Clemons B, Cox J, Sutphin S, Benitez Colon L. Evaluation of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia. <i>2018 Hematology/Oncology Pharmacy Association Annual Conference. Denver, Co.</i>	Mar 2018
Cheung E, McKenzie M, Benitez Colon L, Marini B, Perissinotti A, et al. Impact of standard versus prolonged courses of antibiotics for the treatment of uncomplicated staphylococcus aureus bloodstream infections in patients with hematologic malignancies. <i>2018 Hematology/Oncology Pharmacy Association Annual Conference. Denver, Co.</i>	Mar 2018
Benitez L, Patel T, Rao K, Nagel J. Evaluation of pseudomonas outcomes stratified by carbapenem minimum inhibitory concentration. <i>2016 ASM Microbe Conference, Boston, MA.</i>	Jun 2016
<b><u>Regional Conference</u></b>	
Olanzapine for the Prevention of Emesis in Patients with Multiple Myeloma Receiving High-dose Melphalan Prior to Autologous Transplantation <i>Great Lakes Pharmacy Residency Conference (ACPE accredited). West Lafayette, IN.</i>	Apr 2016
Evaluation of Pseudomonas Outcomes Stratified by Carbapenem Minimum Inhibitory Concentration <i>Great Lakes Pharmacy Residency Conference (ACPE accredited). West Lafayette, IN.</i>	Apr 2015
<b><u>Local (State) Conference</u></b>	
At a Crossroad. Adolescent and young adults with cancer. <i>2024 Advanced Practice Practitioners Oncology Summit. Detroit, MI</i>	Nov 2024
Social Determinants & Cancer Care: Cancer Doesn't Discriminate, but Healthcare Does ACPE accredited presentation. <i>2023 Michigan Society of Hematology/Oncology Pharmacist Forum. Traverse City, MI</i>	May 2023
Oncology Stewardship: A Case-Based Discussion. Invited Keynote Address. <i>Michigan Oncology Quality Consortium Biannual Meeting, virtual.</i>	Jan 2023
Acute Lymphocytic Leukemia: Management Strategies for Young Adult Patients. ACPE accredited presentation. <i>Advanced Practice Practitioners Oncology Summit. Detroit, MI</i>	Nov 2021
Acute Myeloid Leukemia Updates. ACPE accredited presentation. <i>Tennessee Oncology Pharmacist Association Annual Meeting. Nashville, TN.</i>	Sep 2017
Oncologic Stewardship Pharmacy Grand Rounds Presentation <i>Markey Cancer Center pharmacy department presentation (ACPE accredited). UK Healthcare, Lexington, KY.</i>	Jun 2017
Predicting CNS Penetration of Chemotherapeutics: Quite the Headache! <i>University of Michigan Health System (ACPE accredited), Ann Arbor, MI.</i>	Feb 2016
Adverse Effects of Antifungal Agents <i>University of Michigan Health System (ACPE accredited), Ann Arbor, MI.</i>	Feb 2015

## Funding

---

“Oncology Stewardship” Michigan Oncology Quality Consortium (MOQC) CQIO Reserve Fund from Institute for Healthcare Policy & Innovation Collaborative Quality Initiatives. 0.1 FTE funding for 2 years. Co-PI. <https://moqc.org/initiatives/clinical/oncologystewardship/> Jul 2023-Present

## Professional Service and Leadership

---

**HOPA Research & Quality Council member** Aug 2024-Present

**Experiential education committee** Aug 2024-Present  
*University of Michigan College of Pharmacy*

**Pharmacy PharmD admissions committee** Aug 2023-Present  
*University of Michigan College of Pharmacy*

**HOPA Practice Outcomes & Professional Benchmarking Committee (POPBC)** Jun 2023-Present  
Vice-Chair 2024-2025 cycle

**Adolescent Young Adult Acute Lymphoblastic Leukemia Guideline Panel Member** Aug 2022-Present  
*American Society of Hematology*

**Hematology Oncology Research Outcomes (HERO) Consortium** May 2022-Present

- Immediate Past-Chair Jul 2025-Present
- Consortium Chair Jun 2024- Jul 2025
- Chair Elect Jul 2023- Jun 2024
- Regulatory Officer (elected position) May 2022-Jun 2024
- Founding member

**Residency Advisory Committee & Non-Voting Member duties** Aug 2019-Present  
*University of Michigan Health System, Ann Arbor, MI*

- Teaching certificate workgroup member (2020-Present)
- Preceptor appointment workgroup member (2020-2024)
- Resident and Preceptor award committee member (2019-2020)
- Voting member-at-large (2019-2021)

**HOPA News Publication Committee member** Jun 2021-May 2023  
*Hematology Oncology Pharmacy Association*

**Bachelors in Pharmaceutical Science Curriculum Committee member** Aug 2021-May 2023  
*University of Michigan College of Pharmacy*

**Cancer Pharmacy Committee Vice-Chair** Dec 2020-Jul 2022  
*University of Michigan Health System, Ann Arbor, MI*

**Advanced Practice Practitioners Oncology Summit Detroit planning committee** Aug 2020-Nov 2021

**Markey Pharmacy Resident and Learner Research Coordinator** Jan 2017-Jul 2018  
*UKHealthcare, Lexington, KY*

**Cancer Pharmacy Committee Member** Jul 2015-Jun 2016  
*University of Michigan Health System, Ann Arbor, MI*

**Research Series Coordinator** Jul 2014-Jun 2016  
*University of Michigan Health System, Ann Arbor, MI*

**University of Michigan College of Pharmacy Liaison** Jul 2014-Jun 2016  
*University of Michigan Health System, Ann Arbor, MI*

**Post-Graduate Year One Chief Resident**  
*University of Michigan Health System, Ann Arbor, MI*

Jul 2014-Jun 2015

## Teaching and Precepting Experience

### Clinical Associate Professor

Jul 2020-Present

*University of Michigan College of Pharmacy, Ann Arbor, MI*

- Pharm 302 – Personal and Professional Development (Fall 2020, 2021, 2022)
  - Lecturer Fall 2023, Fall 2024; 3 contact hours, 40-50 students
  - Course coordinator Fall 2020, 2021, 2022; 12 contact hours, 40-50 students
  - BSPS Required Curriculum
- Course Co-Coordinator for Pharm 637 – Oncology Elective (Fall 2020 – Present)
  - PharmD Elective Curriculum, 12 contact hours, 20-30 students (P2&P3)
- IPPE Ambulatory care rotation experience (Fall 2020 – Present)
- APPE Ambulatory care rotation experience (Fall 2020 – Present)
- PharmD Investigations project mentor (Fall 2020 – Present)

### Pharmacy Residency Preceptor

Aug 2018-Present

*Michigan Medicine, Ann Arbor, MI*

- Adult Leukemia ambulatory care experience
- Academic Faculty rotation experience
- Mentor for PGY1 and PGY2 writing and research projects
- Member of the Executive Residency Advisory Committee (voting member 2019- 2021)

### Residency and PharmD investigations mentorship -

Years	Residency Rotation	Research (Primary)	Writing (Primary)	Teaching	PDI	Residency mentor
2024-2025	Lana Alhashimi		Lana Alhashimi		Kaitlyn Ziegler Judie Zeni	Michelle Nguyen
2023-2024	Kenton Cooksey Ashlyn Whitesell	Ashlyn Whitesell	Kenton Cooksey	Hadil Shalan Catie Williams	Nhi TranHuyn	Anna Wu Michelle Nguyen
2022-2023	Taylor Gabbard Christy Khouderchah	Kenton Cooksey Isabelle Zerfas		Nour Khadouh Megumi Olsen Marina Capitanov Olivia Ramirez Brianna Groen	Nhi TranHuyn	
2021-2022	Taylor Coe-Eisenberg Christy Khouderchah Liriany Pimentel Lauren Shinn	Taylor Coe-Eisenberg		Conner Ball Amoreena Most Michelle Nguyen Liriany Pimentel Abbey Swery	Nhi TranHuyn	Anisa Bici (RAC)

<b>2020-2021</b>	Madeline Ochs Taylor Coe-Eisenberg Caitlyn Young Brian Bazzell	Kaylee Clark	Madeline Ochs	Taylor Coe-Eisenberg Ryan Sutherland CC Wartman Jacky DeLaPena	Nhi TranHuyn Devon Stonerock	Madison Irwin (Chosen)
<b>2019-2020</b>		Madeline Ochs	Brian Bazzell		Devon Stonerock	Madison Irwin (RAC)
<b>2018-2019</b>	Taylor Weiss				Devon Stonerock	

**Adjunct Clinical Pharmacy Instructor**

*University of Michigan College of Pharmacy, Ann Arbor, MI*

Aug 2018-Jun 2020

- IPPE Ambulatory care rotation experience
- APPE Ambulatory care rotation experience
- PharmD Investigations project mentor
- P706 MUE preceptor
- Lecturer in Course P718 – *Clinical pharmacogenomics in oncology*

**Adjunct Professor, Pharmacy Practice and Science**

*University of Kentucky, Lexington, KY*

Feb 2017-Jul 2018

- PPS966 Oncology – CINV and Chronic Lymphocytic Leukemia
- PPS895 Oncology Elective – CAR-T cells in melanoma
- APPE Inpatient Malignant Hematology rotation experience

**Pharmacy Residency Preceptor**

*University of Kentucky, Lexington, KY*

Feb 2017-Jul 2018

- Inpatient Malignant Hematology rotation experience
- Inpatient Hematopoietic Cell Transplant rotation experience
- Outpatient Hematology/Hematopoietic Cell Transplant rotation experience

*Residency Mentorship*

<b>Years</b>	<b>Rotation</b>	<b>Research (Primary)</b>
<b>2017-2018</b>	E Dan Nichols Erin Hickey Matt McKenzie Kyle Zacholski Laura Cannon	Erin Hickey Matt McKenzie
<b>2016-2017</b>	E Dan Nichols Timothy Mok	

**Languages**

Bilingual: Fluent in English and Spanish